Patrick Soon-Shiong congratulates new FDA leadership on future innovation
@DrPatSoonShiong: Soon-Shiong on FDA leadership
Dr. Patrick Soon-Shiong, a prominent figure in biotechnology, has extended congratulations to the new leadership at the U.S. Food and Drug Administration (FDA).
Representing the interests of the American people and patients, he expressed optimism about the agency's direction. Soon-Shiong emphasized that this leadership change is a ''major step forward'' in maintaining the country's position in innovation and global competitiveness.
The recent appointment of new figures at the FDA signals a pivotal moment for the organization as it seeks to uphold its mission amidst rapidly evolving global standards and technological advancements. ''Innovative approaches and a competitive edge are essential for the U.S. to keep pace with international progress,'' Soon-Shiong noted.
Dr. Makary and Secretary Kennedy, mentioned in the tweet, are expected to lead strategic initiatives that align with these goals, promoting health and safeguarding the interests of patients and stakeholders alike.
Loading...
The FDA's new direction comes as innovation remains at the forefront of the U.S. biomedical landscape—a theme underscored by Dr. Soon-Shiong in his recent discussion of the potential of Bioshield on podcast, which highlighted advances in brain tumor treatments. Further exemplifying his commitment to transformative care, Soon-Shiong has also been instrumental in launching a Long Covid trial in California, reflecting broader efforts to address emerging health challenges through strategic research and leadership.
